PetCaseFinder

Peer-reviewed veterinary case report

Hypercoagulability detected by thromboelastography in dogs

By Fenty, Renee K et al.·Published in Journal of the American Veterinary Medical Association·2011·Department of Clinical Sciences, United States·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Identification of hypercoagulability in dogs with primary immune-mediated hemolytic anemia by means of thromboelastography.

Species:
dog

Plain-English summary

A group of 11 dogs with primary immune-mediated hemolytic anemia (IMHA), a condition where the immune system attacks red blood cells, showed signs of increased blood clotting before starting treatment. Tests indicated that these dogs had faster clot formation and stronger clots compared to healthy dogs. This hypercoagulability (increased tendency to form clots) could lead to serious complications like blood clots. Monitoring and managing this risk is important for dogs diagnosed with IMHA to prevent further health issues.

People also search for: dog IMHA symptoms · dog blood clotting issues · treatment for dog immune-mediated hemolytic anemia

Abstract

OBJECTIVE: To evaluate whole blood hemostasis by means of thromboelastography in dogs with primary immune-mediated hemolytic anemia (IMHA) to determine whether these dogs had evidence of hypercoagulability prior to the administration of immunosuppressant medications, blood transfusion products, or anticoagulant agents. DESIGN: Evaluation study. ANIMALS: 11 client-owned dogs admitted to a teaching hospital for management of primary IMHA and 20 clinically normal dogs. PROCEDURES: Citrated whole blood samples were obtained from all dogs for performance of kaolin-activated thromboelastography. Citrated plasma was harvested from blood samples of dogs with IMHA for plasma-based coagulation testing, including activated partial thromboplastin time, prothrombin time, D-dimer concentration, fibrinogen concentration, and antithrombin activity. RESULTS: Compared with control dogs, dogs with primary IMHA had evidence of hypercoagulability as indicated by a significantly lower median (range) clot formation time (0.8 seconds [0.8 to 2.0 seconds] vs 1.9 seconds [1.3 to 3.8 seconds]), higher median angle (76.1° [59.2° to 84.6°] vs 64.0° [45.4° to 71.0°]), higher median maximum amplitude (75.9 mm [66.3 to 86.3 mm] vs 55.7 mm [49.9 to 63.6 mm]), and higher median clot strength (15,000 dyne/cm(2) [9,900 to 31,400 dyne/cm(2)] vs 6,100 dyne/cm(2) [4,900 to 8,700 dyne/cm(2)]). CONCLUSIONS AND CLINICAL RELEVANCE: Dogs with primary IMHA had hypercoagulability as demonstrated by thromboelastography at the time of initial diagnosis and prior to treatment. Such hypercoagulability may be a precursor to clinically evident thrombosis as a complication of the disease process.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21320015/